KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to $81.7 million.

  • Recursion Pharmaceuticals' Share-based Compensation rose 38.30% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.2 million, marking a year-over-year increase of 76.51%. This contributed to the annual value of $81.7 million for FY2024, which is 52.68% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Share-based Compensation is $81.7 million, which was up 52.68% from $53.5 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Share-based Compensation registered a high of $81.7 million during FY2024, and its lowest value of $4.3 million during FY2020.
  • Its 3-year average for Share-based Compensation is $54.4 million, with a median of $53.5 million in 2023.
  • Data for Recursion Pharmaceuticals' Share-based Compensation shows a peak YoY soared of 245.81% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Share-based Compensation stood at $4.3 million in 2020, then skyrocketed by 245.81% to $14.8 million in 2021, then spiked by 88.04% to $27.9 million in 2022, then spiked by 91.71% to $53.5 million in 2023, then surged by 52.68% to $81.7 million in 2024.